Conference Reports for NATAP

66th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 13-17 2015 Back

High Efficacy of the Combination HCV Regimen Elbasvir and Grazoprevir for 8 or 12 Weeks With or Without Ribavirin in Treatment-Naive, Non-Cirrhotic HCV GT1b-Infected Patients: An Integrated Analysis       Reported by Jules Levin AASLD 2015 Nov 13-17 San Francisco   Serfaty L1; Zeuzem S2; Vierling JM3; Howe A4*; Hwang P4; Robertson M4; Butterton J4; Wahl J4; Barr E4; Haber B4 1Université Pierre & Marie Curie, Paris, France; 2Goethe University Hospital, Frankfurt, Germany; 3Baylor St. Luke's Medical Center, Houston, TX, USA; 4Merck & Co., Inc., Kenilworth, NJ, USA. *Former employee of Merck & Co., Inc.   In Vitro Resistance Analysis of Merck's HCV NS5a Inhibitor MK-8742 Demonstrates Increased Potency AgainstClinical Resistance Variants and Improved Resistance Profile........ http://www.natap.org/2012/EASL/EASL_46.htm   Safety and Antiviral Activity of MK-5172, a Next Generation HCV NS3/4A Protease Inhibitor with a Broad HCV Genotypic Activity Spectrum and Potent Activity Against Known Resistance Mutants, in genotype-1 and -3 HCV-Infected Patients..... http://www.natap.org/2011/hepDART/hepDART_10.htm   MK-5172, the 1st HCV Protease Inibitor with Potent Acyivity Against Resistance Mutations In Vitro........ http://www.natap.org/2010/EASL/EASL_38.htm   AASLD: Resistance Analysis [and activity] of Genotype-1 and -3 HCV-Infected Patients Receiving MK-8742, an HCV NS5A Inhibitor With Potent Antiviral Activity, in a Ph1b Monotherapy Study - (11/05/13)   MK-8742, an HCV NS5A Inhibitor With a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotype-1 and -3 HCV-Infected Patients...... http://www.natap.org/2013/AASLD/AASLD_20.htm